US Equestrian (USEF) announced Aug. 21 that Sept. 1 will serve as the effective start date for disclosure and reporting of horses that are being given medroxyprogesterone acetate (MPA), commonly known as Depo-Provera.

This is a follow-up to the announcement following US Equestrian’s Mid-Year Meeting and the Board of Director’s approval of the recommendation of the USEF MPA Panel.

Competitors are currently allowed to use MPA at USEF-licensed competitions. In an effort to better understand MPA use in horses competing at USEF-licensed competitions, officials will collect MPA disclosure forms. They hope this will allow them to collect data on pharmacokinetic data related to MPA administration, including how long it lasts in horses’ systems.

If a horse has received MPA and is competing at a USEF-licensed competition on Sept. 1 or thereafter, an MPA Disclosure Form must be completed. Forms must be completed on horses that received MPA 90 days or less before the effective date and which are competing on Sept.